Shop
Showing 1057–1072 of 1229 results
-
Article: Stratified Medicine: a call for action
€3.03 Only for registered clients -
Article: Stromal tumour of unknown malignant potential of the prostate: A case report and review of the literature
€3.03 Only for registered clients -
Article: Study on tumour biology and the aging effect of chemotherapeutic treatment in older breast cancer patients
€3.03 Only for registered clients -
Article: Subcutaneous panniculitis-like T-cell lymphoma in an elderly patient: a case report
€3.03 Only for registered clients -
Article: Subgroup analysis of rucaparib in platinum-sensitive, recurrent ovarian carcinoma: effect of prior chemotherapy regimens in ARIEL3
€3.03 Only for registered clients -
Article: Successful and durable disease control after treatment by peptide receptor radionuclide therapy in a patient with disseminated insulinoma: a case report
€3.03 Only for registered clients -
Article: Succinate dehydrogenase B deficient renal cell carcinoma in a young adult with paraganglioma: Management of a rare, hereditary malignancy
€3.03 Only for registered clients -
Article: Succinate dehydrogenase B deficient renal cell carcinoma in a young adult with paraganglioma: Management of a rare, hereditary malignancy
€3.03 Only for registered clients -
Article: Sunitinib reduces physical activity (assessed with a pedometer) in a patient with metastatic kidney cancer: a case study
€3.03 Only for registered clients -
Article: Sunitinib reduces physical activity (assessed with a pedometer) in a patient with metastatic kidney cancer: a case study
€3.03 Only for registered clients -
Article: Sunitinib reduces physical activity (assessed with a pedometer) in a patient with metastatic kidney cancer: a case study
€3.03 Only for registered clients -
Article: Supportive care task force
€3.03 Only for registered clients -
Article: Supportive Care Task Force
€3.03 Only for registered clients -
Article: Supportive care task force meeting
€3.03 Only for registered clients -
Article: Sustained benefit of combined dabrafenib/trametinib in patients with advanced melanoma
€3.03 Only for registered clients -
Article: Sustained survival benefit with tremelimumab and durvalumab as first line treatment for patients with advanced hepatocellular carcinoma: 4-year data from the phase III HIMALAYA trial
€3.03 Only for registered clients
